NasdaqCM - Delayed Quote USD

Inhibikase Therapeutics, Inc. (IKT)

Compare
2.9500
-0.1500
(-4.84%)
At close: January 10 at 4:00:00 PM EST
All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-17,244.9230
-18,085.0430
-17,351.1030
-14,297.0510
-1,129.3550
Investing Cash Flow
-358.0710
11,656.6660
-16,005.7080
--
--
Financing Cash Flow
3,655.1050
8,405.0030
-204.7690
41,093.6710
15,064.4110
End Cash Position
913.4200
9,165.1790
7,188.5530
40,750.1330
13,953.5130
Interest Paid Supplemental Data
-17.4870
--
0.9730
1.1480
6.2490
Capital Expenditure
--
-14.2380
-243.2550
--
--
Issuance of Capital Stock
3,793.6610
8,543.5590
--
41,135.3570
14,791.6110
Issuance of Debt
--
--
--
--
272.8000
Repayment of Debt
-248.9110
--
-248.9110
-42.5340
--
Free Cash Flow
-17,244.9230
-18,099.2810
-17,594.3580
-14,297.0510
-1,129.3550
12/31/2020 - 12/23/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers